Cadrenal Therapeutics, Inc.
CVKD evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CVKD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CVKD
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company developing CAD-1005, a first-in-class selective 12-LOX inhibitor for heparin-induced thrombocytopenia (HIT), with a strategy focused on early- to mid-stage validation and strategic out-licensing.
Key risk: Going concern risk
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates for Cadrenal Therapeutics, Inc..
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company developing CAD-1005, a first-in-class selective 12-LOX inhibitor for heparin-induced thrombocytopenia (HIT), with a strategy focused on early- to mid-stage validation and strategic out-licensing.
- Lead product candidate CAD-1005 is a first-in-class selective 12-LOX inhibitor being developed for heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder [sec · filed 2026-04-21].
- Cash and cash equivalents were $2.4 million as of June 30, 2026 [sec_mda · as of 2026-08-13].
- Net loss for the three months ended March 31, 2026 was $2.5 million, including $0.3 million of non-cash expenses [sec_mda · as of 2026-05-07].
- The company has a going concern uncertainty; if unable to secure strategic partnerships or funding within twelve months, it may be forced to scale back or cease operations [sec_mda · as of 2026-08-13].
- Corporate strategy focuses on building, validating, and positioning its portfolio for strategic out-licensing, portfolio monetization, or commercial co-development partnerships [sec_mda · as of 2026-08-13].
What works
- CAD-1005 is a first-in-class selective 12-LOX inhibitor with a favorable safety profile and renal-protective baseline, targeting a high unmet need in HIT [sec_mda · as of 2026-08-13].
- The company has structured its clinical portfolio into a Cardiac Acute Critical Care Franchise, aiming to maximize asset value through early- to mid-stage validation and robust regulatory profiling [sec_mda · as of 2026-08-13].
- Management is actively pursuing multiple funding avenues including strategic partnerships, out-licensing, non-dilutive grants, and equity financings to extend runway [sec_mda · as of 2026-08-13].
What to weigh
- Cash and cash equivalents were only $2.4 million as of June 30, 2026, with a net loss of $3.3 million for the period, indicating a limited runway [sec_mda · as of 2026-08-13].
- There is substantial doubt about the company's ability to continue as a going concern; if funding is not secured within twelve months, operations may be delayed, scaled back, or ceased [sec_mda · as of 2026-08-13].
- The company has incurred recurring losses and negative cash flows since inception, with no assurance of completing partnering transactions or financings on acceptable terms [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
Lead candidate CAD-1005 is a first-in-class selective 12-LOX inhibitor for HIT.
“Our lead product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia ("HIT"), a deadly immune-mediated thrombotic disorder.”
SEC filings · April 21, 2026
Cash position as of June 30, 2026 was $2.4 million.
“As of June 30, 2026, we had cash and cash equivalents of $2.4 million”
SEC MD&A · August 13, 2026
Going concern uncertainty if funding not secured within twelve months.
“If we are unable to secure strategic partnerships, out-licensing agreements, or alternative non-dilutive funding such as grant funding within the next twelve months, we will lack the financial resources to sustain our operations.”
SEC MD&A · August 13, 2026
Corporate strategy is to out-license or partner early-stage assets.
“Our overarching corporate strategy focuses on building, validating, and positioning our targeted portfolio for strategic out-licensing, portfolio monetization, or commercial co-development partnerships.”
SEC MD&A · August 13, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — Substantial doubt about ability to continue as a going concern; may cease operations if funding not secured within 12 months [sec_mda · as of 2026-08-13].
- Limited cash runway — Only $2.4M cash as of June 30, 2026, with net loss of $3.3M; cash burn likely exceeds current resources [sec_mda · as of 2026-08-13].
- Dependence on partnerships — Strategy relies on out-licensing or partnerships; no assurance of consummating such transactions on favorable terms [sec_mda · as of 2026-08-13].
- Early-stage pipeline — CAD-1005 is still in early- to mid-stage validation; no guarantee of successful clinical development or regulatory approval [sec_mda · as of 2026-08-13].
What to watch
- Ability to secure strategic partnerships, out-licensing agreements, or non-dilutive funding within the next twelve months [sec_mda · as of 2026-08-13].
- Progress of CAD-1005 clinical development and regulatory profiling for HIT [sec_mda · as of 2026-08-13].
- Cash burn rate and any additional equity or debt financings [sec_mda · as of 2026-08-13].
- Execution of the Cardiac Acute Critical Care Franchise strategy and portfolio integration [sec_mda · as of 2026-08-13].
Sources: SEC filings · SEC MD&A · Generated August 15, 2026 · How we verify sources →
Run Cadrenal Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Cadrenal Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
4.5 months
D/E 0.37 · 0% dilution
Lead: Phase 2/Phase 3
2 candidates
No upcoming catalysts tracked
0 buys · 22 sells (180d)
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
12
Total value held
$647K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 90,402 | $463K |
| geode capital management, llc | 21,626 | $111K |
| vanguard fiduciary trust co | 8,311 | $43K |
| blackrock, inc. | 5,496 | $28K |
| osaic holdings, inc. | 300 | $2K |
| morgan stanley | 100 | $512 |
| wells fargo & company/mn | 99 | $507 |
| archer investment corp | 35 | $179 |
| ifp advisors, inc | 30 | $154 |
| ubs group ag | 3 | $15 |
Showing top 10 of 12 institutional holders of Cadrenal Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 2.1%
- Days to cover
- 1.1
- Shares short
- 54,350
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CVKD short interestGovernance
Frequently asked questions
What is the AI investment thesis for Cadrenal Therapeutics, Inc.?
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company developing CAD-1005, a first-in-class selective 12-LOX inhibitor for heparin-induced thrombocytopenia (HIT), with a strategy focused on early- to mid-stage validation and strategic out-licensing.
What is Cadrenal Therapeutics, Inc.'s lead drug candidate?
Cadrenal Therapeutics, Inc.'s most advanced tracked candidate is cad-1005 (Phase 3) for heparin-induced thrombocytopenia ("HIT").
Who is the CEO of Cadrenal Therapeutics, Inc.?
Mr. Quang X. Pham is the chief executive officer of Cadrenal Therapeutics, Inc. (CVKD).
Where is Cadrenal Therapeutics, Inc. headquartered?
Cadrenal Therapeutics, Inc. (CVKD) is headquartered in Ponte Vedra, FL, United States.
What therapeutic areas does Cadrenal Therapeutics, Inc. focus on?
Cadrenal Therapeutics, Inc. develops therapies across Cardiovascular, Hematology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.